Monday, February 26

RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024


Detecting MeVOs and Collateral Assessment with Multimodality AI Approach, by Sowlat et. al.

Improved Stroke Outcomes Following Implementation of RapidAI Platform at Ascension-Illinois, by Malisch et. al.

National database demonstrates substantial delays between non-contrast CT and CT angiography in suspected stroke patients in 2023, by Christina Mijalski Sells, M.D., and, Pina Sanelli, M.D. MPH, FACR.

Article content

  • Data on 23,935 patients from 717 U.S. hospitals using CT and CT angiography (CTA) were processed with RapidAI to determine time delays between the modalities.
  • 18% of all patients had a more than 15-minute delay between NCCT and CTA​, and 6% had a more than 30-minute delay.
  • Even among high-performing hospitals, many patients had a >15-minute delay​ between modalities – reaffirming the potential operational and clinical value of Rapid’s NCCT suite in identifying LVOs on NCCT scans and substantially reducing door-to-diagnosis time.

Three subacute or chronic subdural hematoma (SDH) studies, EMBOLISE, MAGIC-MT, and STEM, were also reported at ISC; all showed positive results demonstrating a reduction in recurrence of the subdural when embolization of the middle meningeal artery (MMA) was used in addition to surgery versus surgery alone. SDH is one of the most common neurosurgical diseases and affects 1-21 per 100,000 patients per year, and the rate of recurrence requiring treatment is 12-20%.1,2,3 Many SDH patients are lost to follow-up. Proper identification and tracking of SDH through technology such as Rapid SDH will be beneficial in identifying patients most suitable for MMA procedures.

“In the world of AI, clinical validation is paramount to instill confidence in clinician decision-making,” said Karim Karti, CEO of RapidAI. “Securing another NEJM publication and sharing results from more than a dozen studies at ISC 2024 reaffirms our lasting and ongoing contribution to enhancing stroke care.”

About RapidAI

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from 12 million scans in more than 2,200 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.

1 Subdural evacuating port system for chronic subdural hematoma: a systematic review and meta-analysis of clinical outcomes, Egyptian Journal of Neurosurgery volume 38, Article number: 76 (2023)
2 Postoperative Course and Recurrence of Chronic Subdural Hematoma, J Korean Neurosurg Soc. 2010 Dec; 48(6): 518–523
3 Controversies in the Surgical Treatment of Chronic Subdural Hematoma: A Systematic Scoping Review Diagnostics 2022, 12(9), 2060

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212631085/en/

logo

Contacts

RapidAI Media Contact:
Jessica Stebing
Group Manager, Marketing Communications
260.336.6202
[email protected]

#distro

Share this article in your social network



financialpost.com

Leave a Reply

Your email address will not be published. Required fields are marked *